AR126614A1 - Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma - Google Patents
Composición farmacéutica de anticuerpo anti-pd-1 y uso de la mismaInfo
- Publication number
- AR126614A1 AR126614A1 ARP220102031A ARP220102031A AR126614A1 AR 126614 A1 AR126614 A1 AR 126614A1 AR P220102031 A ARP220102031 A AR P220102031A AR P220102031 A ARP220102031 A AR P220102031A AR 126614 A1 AR126614 A1 AR 126614A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- seq
- antibody
- amino acid
- injection
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 6
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 238000002347 injection Methods 0.000 abstract 2
- 239000007924 injection Substances 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 abstract 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona una composición farmacéutica de anticuerpo anti-PD-1 estable y el uso de la misma. La composición farmacéutica comprende un tampón y un anticuerpo anti-PD-1 o un fragmento de unión a antígeno del mismo; en donde el anticuerpo antiPD-1 o el fragmento de unión a antígeno del mismo tiene una concentración de aproximadamente 100 - 250 mg/ml y comprende una LCDR1, una LCDR2 y una LCDR3 que tienen las secuencias de aminoácidos establecidas en la SEQ ID Nº 1, SEQ ID Nº 2 y SEQ ID Nº 3, respectivamente, y una HCDR1, una HCDR2 y una HCDR3 que tienen secuencias de aminoácidos establecidas en la SEQ ID Nº 4, SEQ ID Nº 5 y SEQ ID Nº 6, respectivamente; y en donde la composición farmacéutica tiene un pH de aproximadamente 5.0 - 6.5. La presente invención también proporciona una inyección que comprende la composición farmacéutica y el uso de la composición farmacéutica y la inyección en la preparación de un medicamento para tratar una enfermedad o trastorno eliminando, inhibiendo o reduciendo la actividad de PD-1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110863978 | 2021-07-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126614A1 true AR126614A1 (es) | 2023-10-25 |
Family
ID=85086307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102031A AR126614A1 (es) | 2021-07-29 | 2022-07-29 | Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4376809A1 (es) |
| CN (1) | CN116019907A (es) |
| AR (1) | AR126614A1 (es) |
| AU (1) | AU2022320670A1 (es) |
| CA (1) | CA3227991A1 (es) |
| WO (1) | WO2023006055A1 (es) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104250302B (zh) * | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| JP2020512359A (ja) * | 2017-03-29 | 2020-04-23 | セルジーン コーポレイション | Ｐｄ−１結合タンパク質を含む製剤及びそれを作製する方法 |
| MX2019013751A (es) * | 2017-05-16 | 2020-01-15 | Jiangsu Hengrui Medicine Co | Composicion farmaceutica de anticuerpos del ligando 1 de muerte programada y su uso. |
| CN111246886B (zh) * | 2017-11-02 | 2022-03-15 | 正大天晴药业集团股份有限公司 | 一种抗pd-l1人源化单克隆抗体的药物组合物 |
| CN110882385B (zh) * | 2018-09-07 | 2021-07-09 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗肿瘤中的用途 |
| CN112741804A (zh) * | 2019-10-31 | 2021-05-04 | 上海君实生物医药科技股份有限公司 | 含有抗pd-l1抗体的稳定制剂 |
| AU2022207020A1 (en) * | 2021-01-14 | 2023-08-31 | Shanghai Junshi Biosciences Co., Ltd. | Anti-tigit antibody pharmaceutical composition and application thereof |
-
2022
- 2022-07-29 CA CA3227991A patent/CA3227991A1/en active Pending
- 2022-07-29 WO PCT/CN2022/108825 patent/WO2023006055A1/en active Application Filing
- 2022-07-29 CN CN202210929845.3A patent/CN116019907A/zh active Pending
- 2022-07-29 AU AU2022320670A patent/AU2022320670A1/en active Pending
- 2022-07-29 AR ARP220102031A patent/AR126614A1/es unknown
- 2022-07-29 EP EP22848659.3A patent/EP4376809A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022320670A1 (en) | 2024-03-14 |
| EP4376809A1 (en) | 2024-06-05 |
| CN116019907A (zh) | 2023-04-28 |
| CA3227991A1 (en) | 2023-02-02 |
| WO2023006055A1 (en) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| RU2486198C2 (ru) | Антиген, ассоциированный с ревматоидным артритом | |
| PE20210045A1 (es) | Anticuerpos agonistas contra pd-1 y usos de estos | |
| AR079903A1 (es) | Formulacion de anticuerpo y regimenes terapeuticos. envase farmaceutico. kit. | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| RU2013148537A (ru) | Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения | |
| AR081434A1 (es) | Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo | |
| NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
| NZ706986A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| RU2011144312A (ru) | БИСПЕЦИФИЧЕСКИЕ АНТИ-ErbB-3/АНТИ-С-МЕТ АНТИТЕЛА | |
| JP2015526440A5 (es) | ||
| RU2014150548A (ru) | Терапевтическое средство от зуда | |
| AR071891A1 (es) | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| AR069062A1 (es) | Anticuerpo anti-hepcidina | |
| AR091462A1 (es) | Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso | |
| JP2022119854A5 (es) | ||
| UA113728C2 (xx) | Фармацевтична композиція, яка містить антитіло до pcsk9 людини | |
| RU2019139093A (ru) | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение | |
| AR070821A1 (es) | Anticuerpo anti- tyrp1 (antitiroxina humana) | |
| PE20201503A1 (es) | Formulaciones de inmunoconjugado anti-cd79b estables | |
| IL259036A (en) | asct2-specific binding molecules and their uses | |
| SI2791177T1 (en) | Molecules that bind thrombin antibodies and their use | |
| JP2023055904A5 (es) |